NeuroOne Medical Technologies Corporation

NasdaqCM:NMTC Stock Report

Market Cap: US$31.5m

NeuroOne Medical Technologies Management

Management criteria checks 2/4

NeuroOne Medical Technologies' CEO is Dave Rosa, appointed in Jul 2017, has a tenure of 7.5 years. total yearly compensation is $2.00M, comprised of 26.1% salary and 73.9% bonuses, including company stock and options. directly owns 1.38% of the company’s shares, worth $434.11K. The average tenure of the management team and the board of directors is 4.9 years and 6.9 years respectively.

Key information

Dave Rosa

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage26.1%
CEO tenure7.5yrs
CEO ownership1.4%
Management average tenure4.9yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

NeuroOne Medical Technologies: A Small-Cap Electrode Technology Play With Multiple Catalysts Ahead

Dec 10

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Dec 16
Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

Jul 25
Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Apr 11
Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Sep 15
We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

Aug 03

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Jun 02
Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

Dec 18
Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

Nov 19

Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

Sep 04
Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

We're Not Very Worried About NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Rate

May 27
We're Not Very Worried About NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Rate

CEO Compensation Analysis

How has Dave Rosa's remuneration changed compared to NeuroOne Medical Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024US$2mUS$522k

-US$12m

Jun 30 2024n/an/a

-US$12m

Mar 31 2024n/an/a

-US$13m

Dec 31 2023n/an/a

-US$13m

Sep 30 2023US$990kUS$507k

-US$12m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$9m

Dec 31 2022n/an/a

-US$9m

Sep 30 2022US$1mUS$472k

-US$10m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021n/an/a

-US$11m

Sep 30 2021US$2mUS$411k

-US$10m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020n/an/a

-US$11m

Sep 30 2020US$1mUS$404k

-US$14m

Jun 30 2020n/an/a

-US$14m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019n/an/a

-US$10m

Sep 30 2019US$558kUS$392k

-US$7m

Jun 30 2019n/an/a

-US$8m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018n/an/a

-US$6m

Sep 30 2018US$417kUS$288k

-US$7m

Compensation vs Market: Dave's total compensation ($USD2.00M) is above average for companies of similar size in the US market ($USD645.26K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.

CEO

Dave Rosa (60 yo)

7.5yrs

Tenure

US$1,995,745

Compensation

Mr. David A. Rosa, also known as Dave, M.D., serves as an Independent Director of BioRestorative Therapies, Inc. since November 4, 2021. He serves as Director of BlinkTBI, Inc. since July 2023. He serves a...

Leadership Team

NamePositionTenureCompensationOwnership
David Rosa
President7.5yrsUS$2.00m1.38%
$ 434.1k
Ronald McClurg
Chief Financial Officer4yrsUS$598.55k0.40%
$ 127.0k
Christopher Volker
Chief Operating Officer1.2yrsUS$743.17k0.24%
$ 76.5k
Mark Christianson
Co-Founderno dataUS$260.85k0.85%
$ 268.0k
Steven Mertens
Chief Technology Officer5.8yrsUS$457.71k0.16%
$ 50.4k
Hijaz Haris
Vice President of Marketingno datano datano data

4.9yrs

Average Tenure

60.5yo

Average Age

Experienced Management: NMTC's management team is considered experienced (4.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Rosa
President7.5yrsUS$2.00m1.38%
$ 434.1k
Jeffrey Mathiesen
Independent Director7.4yrsUS$120.50k0.28%
$ 88.4k
Paul Buckman
Independent Chairman of the Board7.4yrsUS$169.00k0.35%
$ 111.2k
Edward Andrle
Independent Director4.9yrsUS$119.00k0.21%
$ 65.5k
Robert Gross
Member of Scientific Advisory Board3.6yrsno datano data
Greg Worrell
Chairman of Scientific Advisory Boardno datano datano data
Jamie Van Gompel
Member of Scientific Advisory Boardno datano datano data
Gregory Esper
Member of Scientific Advisory Boardno datano datano data
Justin Williams
Member of Scientific Advisory Boardno datano datano data
Kip Ludwig
Member of Scientific Advisory Board6.3yrsno datano data

6.9yrs

Average Tenure

65yo

Average Age

Experienced Board: NMTC's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 23:09
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NeuroOne Medical Technologies Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Benjamin HaynorAlliance Global Partners
Alexander NowakCraig-Hallum Capital Group LLC